Keyword: U.S. Department of Justice
Sanofi's Bioverativ buy buoyed its rare disease lineup. But for a Swiss man, the deal allegedly brought some illegal gains—and a U.S. criminal case.
Novartis and the feds are close to settling a kickback lawsuit, according to an attorney's letter posted publicly by mistake—and then quickly removed.
When Insys settled with the feds for $225 million, the drugmaker hoped it had put its troubled past behind it. Now they’re filing for bankruptcy.
Chafing under federal kickback charges tied to its H.P. Acthar Gel, Mallinckrodt appeared to be clear with a settlement in the works. Not so fast.
Bad news for Mallinckrodt: Federal prosecutors will join plaintiffs in whistleblower suits alleging illegal marketing of Questcor's H.P. Acthar Gel.
Indivior made billions from fraudulent marketing of its opioid dependence drugs, the feds allege in a new indictment.
Acadia Pharmaceuticals had to defend its Nuplazid safety last year, and now the drugmaker faces a DOJ probe into its marketing.
During Insys founder John Kapoor's criminal trial, prosecutors played a video urging sales reps to break the rules when promoting its opioid Subsys.
Pfizer has joined three Big Pharma peers in a DOJ probe over allegations the companies paid bribes to a terrorist-run Iraqi health ministry.
Targeted by the Justice Department in an industrywide copay assistance investigation, Pfizer has now agreed to a $23.85 million deal with the feds.